Related Experiment Video

Updated: Oct 1, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Hsp90 inhibitors as novel cancer chemotherapeutic agents

Len Neckers1

  • 1Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, 9610 Medical Center Drive, Suite 300, Rockville, MD 20850, USA. len@helix.nih.gov

Trends in Molecular Medicine
|April 3, 2002
PubMed

Insights

Heat shock protein 90 (Hsp90) inhibitors target cancer cell survival proteins. Combining Hsp90 inhibitors with chemotherapy may enhance antitumor efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Heat shock protein 90 (Hsp90) is a molecular chaperone essential for the stability and function of numerous signaling proteins that drive cancer cell growth and survival.
  • Key Hsp90 client proteins include mutated p53, Bcr-Abl, Raf-1, Akt, ErbB2, and hypoxia-inducible factor 1 alpha (HIF-1 alpha).

Purpose of the Study:

  • To investigate the therapeutic potential of Hsp90 inhibitors in cancer treatment.
  • To explore the combination of Hsp90 inhibitors with standard chemotherapeutic agents for enhanced efficacy.

Main Methods:

  • Hsp90 inhibitors interact with a single molecular target, leading to the destabilization and degradation of Hsp90 client proteins.
  • Preclinical model systems were utilized to assess the antitumor activity of Hsp90 inhibitors.
  • One Hsp90 inhibitor, 17-allylaminogeldanamycin (17AAG), is undergoing phase I clinical trials.

Main Results:

  • Hsp90 inhibitors demonstrated promising antitumor activity in preclinical models.
  • The chemoprotective roles of several Hsp90 client proteins suggest potential for combination therapies.

Conclusions:

  • Hsp90 inhibitors represent a targeted approach to destabilize key cancer-promoting proteins.
  • Combining Hsp90 inhibitors with conventional chemotherapy could significantly improve therapeutic outcomes in cancer patients.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.